Elicio Therapeutics
ELTX
18 hedge funds and large institutions have $2.48M invested in Elicio Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
1.76% less ownership
Funds ownership: 6.32% → 4.56% (-1.8%)
7% less capital invested
Capital invested by funds: $2.68M → $2.48M (-$200K)
10% less funds holding
Funds holding: 20 → 18 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$86.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$57K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.21K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$411K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$200K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$48.5K |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$3.1K |
ELTX Hedge Fund Activity: Q3 2024 in Review
18 of the 6,970 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q3 2024, worth a combined $2.48M — down 7.5% from $2.68M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ELTX and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 7 added.
The largest buyer was Northern Trust, adding an estimated $86.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $411K sold.
- 18 institutional investors held Elicio Therapeutics (ELTX) as of Q3 2024, down from 20 in Q2 2024.
- Funds reported $2.48M of Elicio Therapeutics stock for Q3 2024, down 7.5% quarter-over-quarter.
- 3 funds opened new Elicio Therapeutics positions in Q3 2024 and 4 closed out, a net change of -1 holder.
- The largest Elicio Therapeutics buyer in Q3 2024 was Northern Trust, an estimated $86.8K added.
- The largest Elicio Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $411K sold.
Based on aggregated 13F filings for Q3 2024.